Gilead Sciences, Inc. logo
Gilead Sciences, Inc. (GILD)
Compare

Gilead Sciences, Inc. (GILD) Earnings Per Share (EPS): 7.34

popular:market cap|pe ratio|revenue|price history|total return

Is Gilead Sciences, Inc.’s earnings per share (EPS) high or low?

Gilead Sciences, Inc.'s earnings per share (EPS) of 7.34 is 115% above its 5-year average of 3.41, near the high end of its 5-year range (0.10–7.34).

As of Thursday, June 11, 2026. 103.32% above its 12-month average of 3.61.

P/E Ratio|EPS CAGR|Net Income|Earnings Yield|All Metrics

GILD Earnings Per Share (EPS) Chart

GILD Earnings Per Share (EPS)
6.84+1700.00% 1Y
Zoom

GILD Average Earnings Per Share (EPS) Chart

GILD Current vs Average Earnings Per Share (EPS) Chart

GILD Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

7.34

EARNINGS PER SHARE (EPS) AVG TTM

3.61

EARNINGS PER SHARE (EPS) AVG 3Y

3.85

EARNINGS PER SHARE (EPS) AVG 5Y

3.41

EARNINGS PER SHARE (EPS) AVG 10Y

4.99

EARNINGS PER SHARE (EPS) AVG 15Y

4.38

EARNINGS PER SHARE (EPS) AVG 20Y

3.49

CURRENT VS TTM AVG

+103.32%

CURRENT VS 3Y AVG

+90.40%

CURRENT VS 5Y AVG

+115.06%

CURRENT VS 10Y AVG

+47.05%

CURRENT VS 15Y AVG

+67.56%

CURRENT VS 20Y AVG

+110.26%

GILD Competitors' Earnings Per Share (EPS)

NAMEMARKET CAPEARNINGS PER SHARE (EPS)TTM3Y5Y
Gilead Sciences, Inc. (GILD)$156.35B7.343.613.853.41
Abbott Laboratories (ABT)$155.75B3.595.714.664.19
Pfizer Inc. (PFE)$149.61B1.311.392.192.39
Intuitive Surgical, Inc. (ISRG)$144.79B8.257.275.845.20
Thermo Fisher Scientific Inc. (TMO)$176.21B18.1917.1716.9017.22
CVS Health Corporation (CVS)$126.70B2.272.533.714.39
Danaher Corporation (DHR)$126.39B5.175.206.666.73
Amgen Inc. (AMGN)$188.37B14.3710.9711.6711.57
Bristol-Myers Squibb Company (BMY)$116.13B3.56-0.481.470.84
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B16.866.6910.109.99

EPS Comparison

Trailing EPS (TTM)

$7.34

Forward EPS (Est.)

$9.65

P/E Ratio

16.6

Formula: EPS = Net Income / Weighted Average Shares Outstanding

Why EPS matters:

  • Directly impacts stock valuation through P/E ratio
  • Used to calculate dividend coverage and payout ratios
  • Enables comparison across companies of different sizes
  • Growth in EPS often correlates with stock price appreciation

Gilead Sciences, Inc. Earnings Per Share (EPS) Formula & Definition

EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Gilead Sciences, Inc. Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The earnings per share (EPS) for GILD stock is 7.34.
Is Gilead Sciences, Inc.'s earnings per share (EPS) high or low?
Gilead Sciences, Inc.'s earnings per share (EPS) of 7.34 is 115% above its 5-year average of 3.41, near the high end of its 5-year range (0.10–7.34).
What is the TTM average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The TTM average earnings per share (EPS) for GILD stock is 3.61.
What is the 3Y average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The 3Y average earnings per share (EPS) for GILD stock is 3.85.
What is the 5Y average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The 5Y average earnings per share (EPS) for GILD stock is 3.41.
What is the 10Y average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The 10Y average earnings per share (EPS) for GILD stock is 4.99.
What is the 15Y average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The 15Y average earnings per share (EPS) for GILD stock is 4.38.
What is the 20Y average earnings per share (EPS) for Gilead Sciences, Inc. (GILD)?
The 20Y average earnings per share (EPS) for GILD stock is 3.49.

Gilead Sciences, Inc. Earnings Per Share (EPS) History

DATEEARNINGS PER SHARE (EPS)
2025-12-316.84
2024-12-310.38
2023-12-314.54
2022-12-313.66
2021-12-314.96
2020-12-310.10
2019-12-314.24
2018-12-314.20
2017-12-313.54
2016-12-3110.08
2015-12-3112.37
2014-12-317.95
2013-12-312.01
2012-12-311.71
2011-12-311.81
2010-12-311.70
2009-12-311.46
2008-12-311.09
2007-12-310.87
2006-12-31-0.65
2005-12-310.45
2004-12-310.26
2003-12-31-0.04
2002-12-310.05
2001-12-310.04
2000-12-31-0.04
1999-12-31-0.05
1998-12-31-0.04
1997-12-31-0.03
1996-12-31-0.02

Related Metrics

P/E RatioEPS CAGRNet IncomeEarnings YieldAll Metrics

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA
17,600 employees
www.gilead.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
View full financials